Carlyle, SK Capital Partners, and bluebird bio have updated their instructions for stockholders in the ongoing tender offer. Stockholders who previously tendered their shares must re-tender them to comply with the amended agreement. They are required to complete and sign a letter of election and transmittal attached to the Offer to Purchase.
The revised terms allow stockholders to choose between receiving $3.00 per share plus a contingent value right (CVR) of $6.84 per share, or $5.00 per share without a CVR. If no election is made, the original offer of $3.00 per share plus a CVR will apply.
“The bluebird board of directors unanimously approved the amended agreement and recommends that all stockholders immediately tender their shares in support of the transaction,” stated the company’s board.
The transaction involves Carlyle and SK Capital purchasing all outstanding shares of bluebird bio. The parties have obtained necessary regulatory approvals and expect completion following successful tendering by May 29, 2025.
Stockholders holding shares through brokers should be aware of potential processing cutoffs before the deadline. Assistance is available through Innisfree M&A Incorporated at (877) 825-8793.
bluebird bio has been pioneering gene therapy since its founding in 2010, securing FDA approvals for three therapies within two years. The company focuses on severe genetic diseases with significant data sets in ex-vivo gene therapy.
Carlyle is an investment firm managing $453 billion across various segments including Global Private Equity and Global Credit. SK Capital focuses on life sciences and specialty materials sectors, managing approximately $9 billion in assets.
This communication does not constitute an offer or solicitation regarding securities but refers investors to documents filed with the SEC for detailed information about the tender offer process.
